Journal Article Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation

Takeuchi, Shinji  ,  Fukuda, Koji  ,  Yamada, Tadaaki  ,  Arai, Sachiko  ,  Takagi, Satoshi  ,  Ishii, Genichiro  ,  Ochiai, Atsushi  ,  Iwakiri, Shotaro  ,  Itoi, Kazumi  ,  Uehara, Hisanori  ,  Nishihara, Hiroshi  ,  Fujita, Naoya  ,  Yano  , Seiji

108 ( 4 )  , pp.696 - 703 , 2017-04-01 , Japanese Cancer Association = 日本癌学会 / John Wiley & Sons
Malignant pleural mesothelioma (MPM) is characterized by dissemination and aggressive growth in the thoracic cavity. Podoplanin (PDPN) is an established diagnostic marker for MPM, but the function of PDPN in MPM is not fully understood. The purpose of this study was to determine the pathogenetic function of PDPN in MPM. Forty-seven of 52 tumors (90%) from Japanese patients with MPM and 3/6 (50%) MPM cell lines tested positive for PDPN. Knocking down PDPN in PDPN-high expressing MPM cells resulted in decreased cell motility. In contrast, overexpression of PDPN in PDPN-low expressing MPM cells enhanced cell motility. PDPN stimulated motility was mediated by activation of the RhoA/ROCK pathway. Moreover, knocking down PDPN with short hairpin (sh) RNA in PDPN-high expressing MPM cells resulted in decreased development of a thoracic tumor in mice with severe combined immune deficiency (SCID). In sharp contrast, transfection of PDPN in PDPN-low expressing MPM cells resulted in an increase in the number of Ki-67-positive proliferating tumor cells and it promoted progression of a thoracic tumor in SCID mice. Interestingly, PDPN promoted focus formation in vitro, and a low level of E-cadherin expression and YAP1 activation was observed in PDPN-high MPM tumors. These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target. © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Number of accesses :  

Other information